The Wiskott-Aldrich syndrome (WAS) is a severe Xlinked disorder characterized by thrombocytopenia with small sized platelets, eczema of the skin, and immunodeficiency leading to increased susceptibility to infection from all classes of pathogens, as well as a high incidence of lymphoid cancer. The clinical spectrum of the disease extends from a full blown presentation of often lifethreatening illness, to much milder variants characterized only by isolated thrombocytopenia with small platelets (X-linked thrombocytopenia, XLT). Common immunopathologic findings in 'classical' WAS patients include low serum levels of IgM, and increased IgA and IgE; failure to produce antibodies to polysaccharide antigens, skin test anergy and in vitro deficits in T and B cell functions. Sepsis and severe intra-cerebral hemorrhages represent frequent causes of death in WAS boys, and malignancies (mainly non-Hodgkin lymphomas) also occur with increased frequency. the gene mutated in WAS 3 and XLT patients, 4 which encodes a 502-amino acid (aa) product named the Wiskott-Aldrich syndrome protein (WASP). Studies aimed at understanding the function of WASP have defined a preferential pattern of expression in hematopoietic cells 3, 5, 6 and identified a number of cellular interacting partners. Several SH3 domain-containing proteins, including adaptors and cellular kinases (Nck, Fyn, Tec, Itk, Btk, PLC-␥, C-Fgr, Grb-2), have been shown to bind WASP in vitro and in vivo (reviewed in Ref. 2) , thus indicating a potential role for WASP in cytokine and growth factor signal transduction pathways. Evidence of a link between WASP and cytoskeleton re-organization has also derived from studies demonstrating the interaction between WASP and the Cdc42 and Rac small GTPases. [7] [8] [9] Further evidence includes the induction of actin-containing clusters in cells transfected or micro-injected with WASP 8 or WIP, a recently identified WASP-interacting protein. 10 Although the definitive function of WASP remains to be determined, a tentative unifying interpretation of the currently available knowledge would suggest that WASP plays a critical role in cytoskeleton organization of hematopoietic cells (megakaryocytes, lymphocytes), possibly in response to cellular activation.
All clinical aspects of the disease are curable by allo-geneic bone marrow transplantation (BMT) with a success rate of approximately 90% when histocompatible sibling donors are available, 11 or when matched unrelated (MUD) transplants are performed in the first years of life. Conversely, MUD BMTs in older WAS patients and T cell-depleted haploidentical transplants have much less satisfactory outcomes with long-term survival ranging from approximately 15% to approximately 45% complicated by high incidence of graft-versus-host reactions. 12 Unfortunately, HLA-identical donors are not available to the majority of those severely affected WAS patients who are candidates for BMT. These patients could benefit from the development of gene-based therapeutic strategies and the recent identification of the molecular basis of this disorder has opened the way to preliminary testing.
A retroviral vector (GCWASP) which carries the human WASP cDNA (generously provided by Dr S Weissman, Yale University, New Haven, CT, USA) and the neomycin resistance gene (neo) was constructed ( Figure 1 ) and packaged in the gibbon-ape leukemia virus (GALV) envelope using the PG13 cell line. 13 A second retroviral construct (pSAM-EN) 14 sharing the same backbone, but exclusively expressing neo was used as negative control. Epstein-Barr virus (EBV)-immortalized B cell lines (BCLs) were grown from WAS patients with null mutations of WASP and transduced with retroviral supernatants following an optimized gene transfer protocol. 15 After transduction, cells were subjected to G418 selection and analyzed for WASP expression by Western blot technique using a WASP-specific monoclonal antibody. 5 As shown in Figure the transduced WASP protein, we performed immunoprecipitation experiments on WAS BCLs before and after corrective gene transfer. Figure 2b shows the results of a representative experiment demonstrating that the retrovirally expressed WASP was appropriately recognized in liquid phase by specific monoclonal antibodies (lane 4), closely reproducing the finding in BCL from normal donors (lane 1). As expected, no product was precipitable from cell lysates of untransduced WAS BCL (lane 2) nor from the same cells transduced with the control SAM-EN vector (lane 3).
Cell surface defects in WAS blood lymphocytes suggesting impairment of cytoskeletal organization have been described since the mid 1980s, well before the gene responsible for the disease was identified. 16 More recently, the demonstration of the interaction of WASP with key regulators of cytosketal reorganization, Cdc42 and rac, [7] [8] [9] has led to further analysis of the cytoskeleton in WAS cells. These studies have identified abnormal actin rearrangement in WAS T lymphocytes in response to CD3-mediated stimulation, 17 as well as defective filamentous actin (F-actin) polymerization and alpha-actinin distribution in WAS lymphoblastoid cell lines. 18 Because of the limited current knowledge of the specific function of WASP, no assays are available to test directly the function of the retrovirally transduced protein. We therefore chose to observe the effects of WAS gene expression on some of the cytoskeletal abnormalities described in WAS BCLs. Samples were processed and scored (Table 1) by blinded operators. As described in Figure 3 , studies of F-actin distribution in BCLs from normal donors stained with FITC-conjugated phalloidin (FP) showed diffused cytoplasmic reactivity in addition to strong linear positivity at the level of microvilli ( Figure  3a ). In keeping with previous observations, 18 cytoplasmic distribution of F-actin was markedly reduced or abolished in WAS BCLs. In addition, WAS BCLs showed limited numbers of F-actin-positive microvilli which appeared structurally abnormal compared with normal Cytospin preparations, staining, and analysis were performed by blinded operators as described in the legend to Figure 3 . Cytoplasmic reactivity to phalloidin-FITC was expressed as the percentage of total cells present in the cytospin evaluated at a ×40 magnification. The number of cells carrying F-actin-positive microvilli was counted in 10 fields using a ×100 microscope objective. BCL from WAS patient 1 were analyzed before (WAS1) and after gene transduction with the SAM-EN control retroviral vector (WAS1/SAM-EN) or the GCWASP construct (WAS1/GCWASP). BCL from WAS patient 2 were studied before (WAS2) and after gene transfer with GCWASP vector (WAS2/GCWASP). tnc, too numerous to count. 
(a) Normal control BCL showing cytoplasmic and microvillar (inset) expression of F-actin in most cells. (b) WAS patient 2 BCL demonstrating clear reduction of F-actin cytoplasmic distribution. Incomplete, blunted microvilli characterized by only weak F-actin reactivity are observed at higher magnification (inset). (c) WAS patient 2 BCL after GCWASP transduction showing marked increase of F-actin reactivity and presence of cells carrying F-actin-positive microvilli (inset). Similar results were obtained from the analysis of BCL from WAS patient 1 (data not shown). Panel a, b and c: × 40;
insets: × 100. controls (Figure 3b) . In marked contrast, FP staining of WASP-transduced WAS BCLs demonstrated a clear increase of cytoplasmic F-actin to levels comparable with BCLs from normal controls. In addition, we observed the presence of some mature actin-filled microvilli which were not detectable before gene transfer (Figure 3c ). WAS BCLs transduced with the SAM-EN control vector did not show improvement of F-actin distribution and were comparable with untransduced cells (data not shown).
Our results demonstrate that retrovirus-mediated gene transfer can reconstitute normal levels of expression of WASP protein in lymphocytic lines obtained from patients affected with WAS. In addition we show that 'de novo' expression of the WASP protein leads to restoration of normal F-actin cytoplasmic distribution in WAS BCLs. Alhough indirect, this evidence argues for adequate functionality of the newly expressed protein and indicates that gene addition strategies may be exploited for correction of biological defects characteristic of WAS cells. Only a few of the transduced WAS BCLs showed the appearance of mature F-actin-containing microvilli. The reasons underlying these findings are presently unclear. It is possible that the ability of WAS EBV-B cells to produce specialized structures such as microvilli cannot be restored by ectopic expression of WASP or that WASP was not expressed at sufficient levels. Further studies are underway in an attempt to address these issues.
Unregulated expression of WASP has been associated with toxic effects of target cells 8 thus generating concern as to potential detrimental effects of WASP 'ectopic' expression following retroviral transduction. We have generated several NIH 3T3-based retroviral producer clones as well as many WAS BCLs expressing WASP under the transcriptional control of the Moloney murine leukemia virus (MoLV) and have not observed any negative metabolic effects on the transfected/transduced cells. The lack of toxicity in our studies may reflect different levels of WASP expression related to lower wasp copy number per cell or to reduced transcription mediated by the MoLV LTR. Of note, the level of expression of WASP in our transduced WAS BCLs was similar to that physiologically expressed by BCLs from normal controls ( Figure  2 ), whereas the levels of WASP associated with cellular toxicity were achieved only after WASP overexpression. 8 Our current limited knowledge of the regulation of the wasp gene and the specific function(s) of the WASP protein poses obvious limitations to the development of clinical applications of gene therapy for this disease, and a better understanding of the mechanisms linking mutations in the wasp gene to the WAS phenotype(s) is needed before corrective gene transfer can be proposed as a treatment for WAS patients. Murine 'knock-out' models of WAS have recently been generated which show some of the biological defects observed in humans 19 and these animals will constitute an important tool for the assessment of safety and efficacy of gene-based therapies. Moreover, studies need to be performed on patient cells with residual expression of mutated WASP to determine whether 'gene addition' strategies may be hindered by dominant negative effects of the mutant protein over the transduced normal WASP.
Because WAS affects multiple hematopoietic cell types and since allogeneic BMT cures all aspects of the diseases, the hematopoietic stem cell is the ultimate target for corrective gene transfer. Retrovirus-mediated transfer of the WASP cDNA into hematopoietic progenitors of WAS patients does not seem to induce negative effects on differentiation of stem cells, as recently reported in abstract form by Huang et al. 20 The experience from allogeneic BMT for WAS indicates that myeloablation is a necessary prerequisite to successful engraftment of normally WASP-expressing hematopoietic stem cells. 12, 21 This observation suggests that in a gene therapy setting, genecorrected hematopoietic progenitors would not have selective advantage over unmodified stem cells and that myeloblation would probably still be required before reinfusion of genetically engineered cells in order to achieve clinical benefit. In this scenario, high efficiency gene transfer into the hematopoietic stem cells is critical and probably beyond our current technical abilities. 'In vivo' positive selection of transduced progenitors could represent a way to overcome this problem and could be achieved by adding in vivo selectable drug resistance genes (eg MDR, DHFR) to the retroviral vector cassette.
From the analysis of the natural history of the disease, it appears clear that, once the threat of lethal cerebral bleeding threatening mostly infants and young children is reduced, the main causes of death in WAS patients are represented by autoimmunity, sepsis and cancer. Studies of T lymphocytes and T cell lines obtained from WAS patients have demonstrated in vitro defects of antigen receptor-mediated activation and actin polymerization, 17, 22 while transmembrane signaling seems to be defective in lymphoblastoid WAS B cell lines, 23 but not in freshly isolated B lymphocytes. 24 In addition, WASP 'knock-out' mice show defective antigen receptorinduced proliferation in T, but not B lymphocytes. 20 Defective T cell immune surveillance against infections and malignancies may account for the clinical complications appearing in WAS patients in late childhood, adolescency and adulthood, and, therefore, T lymphocyte-directed gene therapy could be proposed as an attempt to restore T cell functions in patients for whom BMT is not available. In such an approach, the inclusion in the vector design of 'fail-safe' mechanisms, such as herpes simplex thymidine kinase, 25 might be used to allow elimination of transduced cells in the case of unwanted consequences of WASP expression. Our experiments are particularly relevant to this respect since they demonstrate the feasibility of 'in vitro' corrective gene transfer into mature patients' lymphoid cells and form the basis for further evaluations of therapeutic approaches for WAS based on retrovirus-mediated gene transfer.
